** Sun Pharmaceutical SUN.NS gains 4.4% in holiday-curtailed week; set for best weekly performance since late September 2024
** Drugmaker top weekly gainer on Nifty 50 .NSEI and pharma .NIPHARM indexes
** SUN gained in all sessions this week after $355 million deal for Checkpoint Therapeutics CKPT.O
** Analysts backed the deal, saying it would complement SUN's specialty portfolio
** Stock rated "buy" on avg, per data compiled by LSEG
** YTD, SUN down 11% vs NSEI's 4.7% drop
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.